Use of the 22C3 anti–PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms

BACKGROUND: For non–small cell lung cancer (NSCLC), treatment with pembrolizumab is limited to patients with tumours expressing PD-L1 assessed by immunohistochemistry (IHC) using the PD-L1 IHC 22C3 pharmDx (Dako, Inc.) companion diagnostic test, on the Dako Autostainer Link 48 (ASL48) platform. Opti...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:PLoS One
Auteurs principaux: Ilie, Marius, Khambata-Ford, Shirin, Copie-Bergman, Christiane, Huang, Lingkang, Juco, Jonathan, Hofman, Veronique, Hofman, Paul
Format: Artigo
Langue:Inglês
Publié: Public Library of Science 2017
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5552229/
https://ncbi.nlm.nih.gov/pubmed/28797130
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0183023
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires